Martin Unverdorben

5PUBLICATIONS
24CO-AUTHORS
Major global burdens of diseaseCardiovascular medicine and haematology not elsewhere classifiedHealth and ecological risk assessmentHaematologyCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 25, 2025
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF Registry.

Giuseppe Boriani, Paulus Kirchhof, José Antonio Gordillo de Souza

|May 15, 2025
Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial.

George D Dangas, Martin Unverdorben, Johny Nicolas

|Mar 31, 2025
Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: results from the noninterventional Global ETNA-AF programme.

Doralisa Morrone, Leon Dinshaw, José Antonio Gordillo de Souza

|Jan 10, 2025
Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial.

Robert S Semco, Regan W Bergmark, Sabina A Murphy

|Dec 01, 2020
Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.

M Unverdorben, C von Heymann, A Santamaria

Pageof 1

Frequent Collaborators

2 joint publications

Cathy Z L Chen

2 joint publications

Yukihiro Koretsune

2 joint publications

Paulus Kirchhof

1 joint publications

Robert S Semco